Welcome back everyone, cancer is never a fun story to talk about and so I’m always excited
to share with you stocks with game changing solutions to beat it.
There are so many types of cancer out there but in today’s video, I bring you updates
on one stock which is making progress on a solution for colorectal cancer, which is the
2nd most lethal form of cancer in the United States.
This stock has a small cap valuation at $158m market cap, but when you look at one of its
other peers with an $8.3bn market cap, it gives you the size of the opportunity we have
here should they be successful with their FDA approvals.
So you certainly don’t want to miss having this one on your watchlist and make sure you
stick around to the end so you hear from the CEO sharing insights on their approach to
the FDA approval.
I’ve also now stepped up my stock picks for the channel to identify top stocks like
this one, using some of the best insights from Seeking Alpha and Simply Wall Street.
And so if you want to improve your stock selection, to ensure you’re onto the winners and high
quality gems, you want to check out Simply Wall Street or Seeking Alpha who are offering
some great deals right now.
I mean, a 30% discount with a 14days extended free trial from Simply Wall Street and $40
off Seeking Alpha premium plan, for a very limited time period only, so clearly some
decent cashbacks opportunities right there for you, so we all win together in these tough
times..
So if you really want to bank some the best buy the dip opportunities out there right
now, you really need to make sure you grab your limited time discounts from the links
below.
YouTube also tells me only about 23% of my viewers are subscribed to the channel, so
if you are not subscribed yet, please consider subscribing with all notifications turned
so you get all video updates instantly..
So with that out of the way, please drop a quick like on this video and let’s talk
about Mainz Biomed (NASDAQ:MYNZ) which is now sitting at $11.34 per share, with a market
cap of $158m.
Mainz’ share price is down 11% over the past month which is a decent performance given
the current market environment but it is even better when you look at their performance
over the last 6m as they are actually sitting up 40% in this period of deep losses.
But what stands out in the past performance is the more than 200% jump earlier in January,
where they reached a peak share price of over $27 per share.
This was on the back of some major acquisition for exclusive rights to novel MRNA biomarkers
which was followed by another partnership to do a clinical study with this novel MRNA
which the market cheered very much.
And this was because, these Biomarkers Demonstrated Unique Ability to Identify Curable Early-Stage
Colorectal Cancer.
So in essence, their milestones are very market sensitive, so when you look at the catalysts
for the year, Mainz presents lots of opportunities over the short to medium term.
So here’s what’s new with Mainz.
Mainz BioMed develops market-ready molecular genetic diagnostic solutions for life-threatening
conditions.
Their clinical laboratory tests, save costs and lives by enabling early detection and
prevention of disease.
So patients with cancers and other conditions are living longer and enjoying better health
because of medical revolutions in diagnostic technology.
At its center, are genetic and genomic tests, that identify the unique genetic profile of
individual patients or their disease, and allow physicians to tailor treatment to those
unique characteristics.
Colorectal cancer is the 2nd most lethal cancer in the US, but also highly preventable; with
early detection providing 5-year survival rates above 90%.
Colorectal cancer begins when cells in the intestine undergo genetic mutations.
Which is tumor cells shedding into the intestines.
It requires about 37mn tests per year in the US alone which is a $3.7bn market opportunity.
And recent FDA decisions suggest that screening should be conducted once every three years
starting at the age 45.
And currently, there are 112 Million Americans aged 50+, a total that is expected to increase
to 157 million within 10 years.
Their flagship product is the Coloalert, which is a PCR-based molecular genetic early detection
test, which is non-invasive, requires no preparation or sedation, or time off work, and is designed
to offer affordable colorectal cancer screening solutions.
The coloAlert utilizes proprietary methods to analyse the cell DNA for specific tumor
markers and is designed to detect tumor DNA and detect 85% of colorectal cancer cases
- often in the earliest stages of the disease.
So their ease-of-use drives ongoing patient adherence as the ColoAlert method requires
very small samples compared to the competitor product, ColoGuard.
They have had a strong clinical performance of the first generation coloalert products
and they are looking to launching an over 10,000+ patient study in the U.S. for their
FDA application.
But before we go any further, let’s hear from their CEO Guido Baechler, on their approach
and partnership to FDA approval in the US.
How interesting?
They have a
strong and diverse management team led by GUIDO BAECHLER who has 30 years of global
experience leading public & private life science companies with sustained revenue and EBITDA
growth.
And CORINNA GORGES, their HEAD OF R&D established the first ColoAlert technology transfers to
renowned laboratory partners and has broad knowledge in diverse biomolecular methods.
So some decent collective experiences across their leadership team.
MAINZ SUCCESSFULLY COMPLETED THE CONFORMITY ASSESSMENT TO In Vitro Diagnostic Devices
Regulation IVDR ACHIEVING NEW LEVEL OF EU REGULATORY COMPLIANCE.
They announced that they had successfully completed the conformity assessment of their
internal processes to In Vitro Diagnostic Devices Regulation (IVDR) compliance, which
becomes mandatory from May 26, 2022.
Additionally, the ColoAlert patient kit is now CE marked to the IVDR requirements, a
significant milestone and achievement for the company.
The new, harmonized IVDR regulatory framework has been established to ensure the safety
and performance of in-vitro diagnostic medical devices in the European market.
Their CEO commented that“As a fast-growing organization and one looking to steadily unlock
new global markets, it’s essential that they have watertight compliance across EU
and other key jurisdictions.
MAINZ & DANTE LABS ALSO ANNOUNCED A PARTNERSHIP FOR THE COMMERCIALIZATION OF COLOALERT IN
EUROPE AND THE UNITED ARAB EMIRATES (UAE).
They announced a partnership for the commercialization of ColoAlert in Italy and the United Arab
Emirates (UAE) for ColoAlert, Mainz’s flagship product, which is a highly efficacious and
easy to use at-home detection test for colorectal cancer (CRC).
Dante Labs is a global leader in genome sequencing with a product development and commercial
franchise, focused on providing personalized preventive healthcare solutions by leveraging
its robust databases and proprietary software platform to offer next-generation diagnostic
tools direct to consumers and healthcare professionals.
Inherent to Dante Lab’s business model, is managing state-of-the-art genomic sequencing
laboratories in multiple international regions, and operating a robust e-commerce platform.
And the partnership will first launch ColoAlert in Italy and UAE using Dante’s various established
commercial channels.
So in summary, Mainz Biomed aims to become a leader in the multi-billion-dollar colorectal
cancer diagnostics market which has a $3.7 Billion total addressable market in the U.S.
alone and their current valuation holds tremendous upside, so clearly an opportunity to have
on your watchlist.
So some very very interesting and mindblowing prospects ahead for these penny stocks but
only consider getting in if the price is right for you and if you fully understand the risks.
This video is not financial advice, a buy or a sell recommendation, but is meant to
bring some new and exciting penny stocks to your attention for you to do your own research..
As always I would love to hear from you, so please let me know your thoughts on these
top penny stocks in the comments section below and what other penny stocks are catching your
eyes lately.
And If you are new to my channel, please ensure to subscribe and hit the bell so you are notified
when I upload new videos.
If you would like to see more videos like this, please check out this video right here
or this playlist right here to watch equally insightful content from the channel.
Thank you so much for being here and I look forward to have you in my next video.
Thank you